Evidence map›Paper›PMID 30629183›Full record

ArticleThe Journal of clinical endocrinology and metabolism2019

Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth.

Husam Ghanim, Sandeep Dhindsa, Manav Batra, Kelly Green, Sanaa Abuaysheh, Nitesh D Kuhadiya, Antoine Makdissi, Ajay Chaudhuri, Paresh Dandona

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. FGF-2-dependent signaling activated in aged human skeletal muscle promotes intramuscular adipogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Androgen-Regulated Cardiac Metabolism in Aging Men.Frontiers in endocrinology · 2020
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Husam GhanimDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
Sandeep DhindsaDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
Manav BatraDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
Kelly GreenDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
Sanaa AbuayshehDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
Nitesh D KuhadiyaDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
Antoine MakdissiDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
Ajay ChaudhuriDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
Paresh DandonaDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Williamsville, New York 14221.
University at Buffalo, State University of New York · USSaint Louis University · US

Funding

Testosterone effects on insulin sensitivity & inflammation in T2DM and obesityR01DK075877 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DANDONA, PARESH · 2009 to 2012
$2.3M
NIDDK NIH HHS R01 DK075877
6 · The paper itself

Abstract

contextFibroblast growth factor (FGF)2 is an important stimulatory modulator of satellite cells in skeletal muscle. Satellite cells play a cardinal role in muscle growth and repair.

objectiveWe evaluated whether skeletal muscle expression of FGF2 and muscle growth and differentiation factors are reduced in patients with hypogonadotropic hypogonadism (HH) and whether testosterone replacement therapy results in their restoration.

designThis is a secondary analysis of a previously completed trial of testosterone replacement in men with type 2 diabetes and HH.

settingClinical Research Center at a university. PATIENTS: Twenty-two men with HH and 20 eugonadal men were compared at baseline.

interventionsTwelve men with HH were treated with intramuscular injections of 250 mg testosterone every 2 weeks for 22 weeks, and 10 men received placebo injections. Quadriceps muscle biopsies and blood samples were obtained before and after testosterone therapy. OUTCOME MEASURES AND

resultsThe expression of FGF2 and FGF receptor (FGFR)2 in skeletal muscle of men with HH was significantly lower than that in eugonadal men by 57% and 39%, respectively (P < 0.05). After 22 weeks of testosterone, the expression of FGF2 increased, whereas that of myogenic regulatory factor (MRF)4 and myostatin decreased significantly. There was no change in expression of FGFR2, myogenin, or myogenic differentiation protein in the skeletal muscle. Plasma FGF2 and IGF-1 concentrations increased after testosterone therapy.

conclusionsThese data show that testosterone is a major modulator of FGF2, MRF4, and myostatin expression in skeletal muscle. These effects may contribute to the increase in muscle mass after testosterone therapy.

Indexed as

AdultAgedFibroblast Growth Factor 2HumansHypogonadismInsulin-Like Growth Factor IMaleMiddle AgedMuscle, SkeletalMyogenic Regulatory FactorsMyostatinReceptor, Fibroblast Growth Factor, Type 2TestosteroneFibroblast Growth Factor 2Insulin-Like Growth Factor Imyogenic factor 6Myogenic Regulatory FactorsMyostatinReceptor, Fibroblast Growth Factor, Type 2Testosterone

Identifiers

PMID30629183
PMCPMC6481910
OpenAlexW2909154817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.